By Jim Daly and Marc Pelletier
National news outlets rarely focus on biocontainment, but with the recent Ebola outbreak flooding the media, there is more attention being paid to best practices. And yet pharmaceutical companies and consultants like CRB have worked for decades to understand the strategies that are inherent in implementing biocontainment in biomanufacturing—practices that can be applied across research and healthcare settings.
Often, success comes down to one key factor: people. Beyond patient quarantine, health care facilities must consider all the people and materials that flow in and out of their facilities, the behavior and practices of those people, how quarantined objects will be sanitized or destroyed, and much more. Biocontainment goes far beyond patient quarantine; despite what’s in the news, isolating people isn’t the entire solution.
Successful biocontainment strategies are holistic, with a focus on defining boundaries, training, careful logistics and consistent implementation. People are the greatest risk to biocontainment and so our goal is repetitive and robust protection of all staff and non-staff occupants, which can include visitors and even the patients themselves.